Cargando…

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients

BACKGROUND: Natalizumab is an effective treatment in relapsing-remitting multiple sclerosis (MS). Mainly because of the risk of progressive multifocal leukoencephalopathy (PML), a substantial proportion of John Cunningham (JC) virus–positive patients switch to fingolimod. Previous reports show a cle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leurs, Cyra E, van Kempen, Zoé LE, Dekker, Iris, Balk, Lisanne J, Wattjes, Mike P, Rispens, Theo, Uitdehaag, Bernard MJ, Killestein, Joep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174622/ https://www.ncbi.nlm.nih.gov/pubmed/28823223 http://dx.doi.org/10.1177/1352458517726381

Ejemplares similares

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Disease activity following pregnancy-related discontinuation of natalizumab in MS
por: Kleerekooper, Iris, et al.
Publicado: (2017)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Infusion-related events during natalizumab: No need for post-infusion monitoring
por: Loonstra, Floor C, et al.
Publicado: (2019)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2021)

Fingerprick blood samples to measure serum natalizumab concentrations
por: Toorop, Alyssa A, et al.
Publicado: (2022)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
por: Toorop, Alyssa A., et al.
Publicado: (2020)

Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?
por: Dekker, Iris, et al.
Publicado: (2019)

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment
por: Leurs, Cyra E, et al.
Publicado: (2017)

Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab
por: van Kempen, Zoé L.E., et al.
Publicado: (2022)

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML
por: Wijburg, Martijn T., et al.
Publicado: (2016)

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod
por: de Jong, Brigit A., et al.
Publicado: (2018)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)

Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis
por: Balk, Lisanne J, et al.
Publicado: (2017)

Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis
por: Dekker, Iris, et al.
Publicado: (2017)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients
por: van Kempen, Zoé LE, et al.
Publicado: (2021)

Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers
por: Coric, Danko, et al.
Publicado: (2017)

Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study
por: Balk, Lisanne J., et al.
Publicado: (2016)

Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
por: Sinnecker, Tim, et al.
Publicado: (2016)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018)

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
por: Barbin, Laetitia, et al.
Publicado: (2016)

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021)

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
por: Klotz, Luisa, et al.
Publicado: (2015)

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
por: Butzkueven, Helmut, et al.
Publicado: (2022)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
por: Palomares Cabeza, Virginia, et al.
Publicado: (2022)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort
por: Braune, Stefan, et al.
Publicado: (2013)

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
por: Grahl, S., et al.
Publicado: (2021)

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study
por: Fox, Robert J., et al.
Publicado: (2014)

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
por: Santiago-Setien, Pilar, et al.
Publicado: (2023)

Emerging safety issues in alemtuzumab-treated MS patients
por: Killestein, Joep, et al.
Publicado: (2019)

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
por: Hernández-Preciado, Martha Rocio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jjajjbiocu294s0qpn59snpujn